Letters canceling funding, which abruptly halts millions of rand worth of HIV and TB research grants sponsored by the U.S. government at South African universities, began arriving over the weekend. According to an impacted researcher, it’s expected that more than 300 such grants will be terminated by the end of Sunday. This situation has significant repercussions for higher education and research institutions, including substantial job cuts.
Certain specialists approximate that around 70% of South Africa’s medical research funding, equivalent to approximately $400 million (roughly R7.2 billion) including both primary and subsidiary grants from the previous fiscal year, originates from the National Institutes of Health (NIH). The NIH comprises numerous components supporting this significant contribution.
27 institutes and centres
Each initiative targets a particular field of study. The NIH funds roughly seventy-five percent of global biomedical research.
On Friday night, the University of the Witwatersrand hosted an event.
Wits Health Consortium
The unit responsible for managing the institution’s clinical trials and donor-funded initiatives has received termination notices for all parts of a $2.5 million (approximately R460 million) grant, which concludes in November 2027. This particular grant was provided via the NIH.
National Institutes of Allergy and Infectious Diseases
.
Letters canceling funding, issued on behalf of the chief grants management officer at USAID, Emily Linde, appear to follow a typical format. These letters inform researchers that their projects “fail to advance understanding of biological processes, yield minimal financial benefits, and do not improve public well-being, longevity, or disease reduction.” Additionally, they suggest these initiatives may negatively impact “the wellbeing of American citizens.”
The Wits project was conducted
by lead researchers Helen Rees, who heads the
Wits Reproductive Health Institute
, with Ian Sanne leading the Clinical HIV Research Unit and now also contributing to the international development organization,
Palladium
as its
chief medical officer
.
Ironically, our grant concluded on Human Rights Day, a time meant for aiding and protecting those who are most susceptible,” Sanne said to Bhekisisa. “Now, however, the U.S. government is compelling us to act contrary to these principles. Abruptly halting study participation could place trial volunteers in harm’s way. Does this align with global ethical standards for human research?
The study, ongoing since 2007, came under the
The Wits Research Group Clinical Trials Unit,
and carried out HIV and TB prevention and treatment studies, along with clinical trials for hepatitis and HIV-associated cancers.
Letters of termination were received on Human Rights Day
Other grants that have apparently been terminated up until now encompass research initiatives at the
Center for AIDS Research Program in South Africa
, Caprisa,
headed up
by Salim and Quarraisha Abdool Karim
Several South African universities, which received sub-grants for health research from U.S. institutions like Columbia University in New York, received cease-and-desist directives on Friday following the loss of funding by the American entities. At present, these South African organizations wish to remain unnamed.
Science magazine
reports
The ex-leader of the South African Medical Research Council, Glenda Gray was informed that her $3.1 million (approximately R56.5 million) grant for a clinical trial unit in Soweto [operated via Wits] has shifted from an approved to a pending status.
The
Center for AIDS Research Program in South Africa
, Caprisa,
headed up
By Salim and Quarraisha Abdool Karim, who receive substantial funding from the NIH, is currently on high alert. “So far, we haven’t gotten any notices of termination for our NIH grants,” said Salim Abdool Karim to Bhekisisa early Sunday morning.
TB funding ends as the US confronts TB outbreaks.
Throughout the years, certain HIV prevention research conducted within Sanne’s and Rees’s initiative has focused on populations more susceptible to contracting HIV. These include adolescent girls and young women in Africa, transgender individuals, and female sex workers.
The cancellation email mentioned that their “award no longer aligns with agency goals” and noted that “research programs focused mainly on artificial and nonscientific criteria, such as vague equity aims, go against scientific exploration, fail to broaden our understanding of living organisms, yield minimal benefits for investments made, and ultimately do not improve health outcomes, extend lifespan, or decrease illnesses.”
Worst of all, the note said, “so-called diversity, equity, and inclusion (“DEI”) studies are often used to support unlawful discrimination on the basis of race and other protected characteristics, which harms the health of Americans. Therefore, it is the policy of NIH not to prioritise such research programmes.
The allusions in the letter to diversity, equity, and inclusion probably pertain to the work conducted at Wits regarding transgender individuals and female sex workers—categories of people disapproved of by the Trump administration.
On the evening of his inauguration, which took place on January 20, the president
signed an executive order
banning people’s right to identify as transgender or non-binary individuals. There are only two genders, the executive order declared: male and female.
However, Sanne argues that the mentions of DEI in their letter are not logical. Despite having conducted some studies on communities like transgender individuals and sex workers, much of their work centers around developing efficient treatments for pediatric tuberculosis and improving medications for those with multi-drug resistant TB, along with focusing on preventative measures against TB.
In numerous aspects, our work aligns perfectly with President Trump’s vision of ‘making America great.’ It enhances American safety, strength, and prosperity by safeguarding citizens from tuberculosis-related illnesses. Moreover, a significant portion of the patents and intellectual property for the novel medications we evaluate belong to U.S.-based firms.
SUBHEAD: Experts weigh in
Linda-Gail Bekner, who leads the Desmond Tutu Health Foundation at the University of Cape Town and also obtains NIH funding, cautions that this further setback to our clinical research sector occurs when new TB infections are ”
are at their peak levels in many years within the USA
”.
Kansas is presently experiencing the biggest tuberculosis outbreak that the United States has witnessed in this period.
past 30-40 years
(TB is a condition that has been well-managed in the U.S. for many years.) Furthermore,
60TB of data related to disease cases, along with two fatalities, have been reported.
.
By Saturday, Bekker hadn’t gotten a cancellation letter regarding her grant, yet she states: “Reducing the impact of HIV and TB epidemics to the point where they no longer pose a major public health risk is a matter of worldwide importance. South Africa has taken considerable steps and made notable contributions toward advancing this cause.”
Yogan Pillay, who leads HIV and TB initiatives at the Gates Foundation – an organization that also supports HIV andTB research and stands to be affected by U.S. government budget reductions – cautions: “These cuts will halt progress in both prevention and treatment of HIV. As a result, eradicating or even controlling AIDS has become nothing more than an illusion, with HIV continuing to proliferate.”
“It’s absolutely tragic.”
Trump stated, “Corrective action cannot be taken here.”
The Wits project conducted significant TB research. One
study
Published in February and featured on the NIH website, this study examined the effectiveness of administering double doses of the antiretroviral medication dolutegravir in TB patients.
Previous trials looked at
How secure was it for expectant mothers with HIV to use preventative tuberculosis medication?
, at how effective long-acting, injectable versions of antiretroviral therapy are
worked for teens
And how effective this bi-monthly HIV injection is
worked
.
Sanne states, “It’s unimaginable that [the alleged] Elon Musk-led governmental office for efficiency doesn’t grasp that there is more going on beyond merely DEI initiatives through HIV and various other research endeavors.”
The email stated: “While NIH typically opts for suspending (instead of outright terminating) a grant and provides the recipient a chance to undertake necessary corrective actions prior to making a final termination decision, such measures cannot be taken in this instance.”
The essence of this award is at odds with the agency’s goals, and no changes to the project would bring it in line with these priorities.
Terminations not unexpected
However, the termination of the grants was not unforeseen — or at least not since last week.
On March 12,
Science magazine reported
Matthew Memoli, who was serving as the acting director of the NIH, requested officials at the institute to assemble lists of grants related to South Africa. This email mirrored the phrasing used in previous NIH inquiries that resulted in the cancellation of numerous grants focused on areas such as transgender health, vaccine hesitance, and others not supported by the current administration.
At least
300 US university projects
have also had their grants revoked by the Trump administration, with numerous institutions being US universities.
resulting in demonstrations throughout the United States
.
These terminations are part of what the Trump administration views as cost-saving measures or research that doesn’t align with their beliefs, and such cuts are expected to keep happening globally.
SA researchers have initiated discussions with philanthropic foundations and the government to provide financial support, according to Sanne, who notes that “there haven’t been definite results” yet.
Projects in South Africa that received cancellation notices were informed that they had the opportunity to “contest and submit data and documents refuting” their termination decisions.
However, they must initially go through a “first-level grant appeal process” which needs to be completed before they can proceed to “file an appeal with the departmental appeals board.”
If projects decide to contest the decision, they must file an appeal within 30 days of receiving their termination notice.
Sanne mentions his intention to utilize the appeals process, and should those efforts not succeed, he aims to negotiate an ethical and responsible method for terminating the trials. “Our research saves lives, and the NIH has supported us in this endeavor,” he states. “Now, what we must do is persuade them of the importance of continuing our work instead of ending decades of investment which could lead to the loss of many lives.”
The Gates Foundation is referenced in this piece. Although Bhekisisa receives financial support from the Foundation, it maintains its independence in editing and content decisions.
This tale was crafted by the
Bhekisisa Center for Health Journalism
. Register for the
newsletter
.
Provided by Syndigate Media Inc. (
Syndigate.info
).